0 180

Cited 93 times in

Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma

Authors
 Su Jung Shim  ;  Jinsil Seong  ;  Kwang Hyub Han  ;  Chae Yoon Chon  ;  Chang Ok Suh  ;  Jong Tae Lee 
Citation
 LIVER INTERNATIONAL, Vol.25(6) : 1189-1196, 2005 
Journal Title
 LIVER INTERNATIONAL 
ISSN
 1478-3223 
Issue Date
2005
MeSH
Antibiotics, Antineoplastic/administration & dosage ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/radiotherapy ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic* ; Combined Modality Therapy ; Doxorubicin/administration & dosage ; Female ; Gelatin Sponge, Absorbable ; Humans ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Liver Neoplasms/radiotherapy ; Liver Neoplasms/therapy* ; Male ; Middle Aged ; Radiotherapy Dosage ; Survival Rate
Keywords
Adriamycin ; chemoembolization ; Gelform ; hepatocellular carcinoma ; radiotherapy ; survival
Abstract
PURPOSE: In order to determine the effect of additional radiotherapy (RT) after an incomplete transcatheter arterial chemoembolization (TACE) in an unresectable hepatocellular carcinoma (HCC), the treatment results of patients receiving TACE plus RT were analyzed and compared with those treated with TACE alone. MATERIALS AND METHODS: One hundred and five patients with an unresectable HCC were treated with TACE from January 1992 to December 2002. In 73 of these patients, the TACE was incomplete. Among them, TACE was repeatedly performed in 35 patients (TACE group), and the remaining 38 patients were also treated with local RT (TACERT group). The patients were either in stage III or IVa, Eastern Cooperative Oncology Group 2 or less, and Child-Pugh class A or B. The average frequency of TACE prior to RT was 2 and the RT was started within 7-10 days after the TACE. RESULTS: The 2-year survival rate was significantly higher in the TACERT than in the TACE group (36.8 % vs. 14.3%, P=0.001). According to the tumor size, the 2-year survival rates in the TACERT and TACE groups were 63% vs. 42% in 5-7 cm (P=0.22), 50% vs. 0% in 8-10 cm (P=0.03), and 17% vs. 0% in larger than 10 cm (P=0.0002) respectively. CONCLUSION: There was a significantly improved survival rate in the TACERT group of unresectable HCC patients than in the TACE group, particularly in case of tumors > or =8 cm in diameter. Therefore, RT in addition to TACE is strongly recommended for patients with an unresectable HCC.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2005.01170.x/abstract
DOI
10.1111/j.1478-3231.2005.01170.x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Suh, Chang Ok(서창옥)
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Shim, Su Jung(심수정)
Lee, Jong Tae(이종태)
Chon, Chae Yoon(전재윤)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/150496
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links